Ludwig Kappos - Articles and news items

Genzyme logo

European Commission approves Genzyme’s once-daily, oral multiple sclerosis treatment Aubagio® (teriflunomide)

Industry news, News / 30 August 2013 / Sanofi

Sanofi and its subsidiary Genzyme announced that the European Commission has granted marketing authorization for Aubagio® (teriflunomide)…


Genzyme presents second Phase III study of once-daily oral AUBAGIO® (teriflunomide) confirming significant impact on disability

Industry news, News / 12 October 2012 / Sanofi

Sanofi and Genzyme announced that key data from the TOWER trial were presented at the 28th Congress of the ECTRIMS…

Novartis gains approval for Gilenya® as a first-line disease modifying oral therapy for multiple sclerosis in Switzerland and Australia

Industry news, News / 24 January 2011 / Novartis

Swissmedic and TGA have granted approval for Gilenya® (fingolimod)…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...